Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dapagliflozin Post-Marketing Surveillance in Heart Failure Patients and Chronic Kidney Disease Patients

NCT05134701 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05134701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05134701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dapagliflozin Post-Marketing Surveillance in Heart Failure Patients and Chronic Kidney Disease Patients
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
March 10, 2022
Completion date
May 20, 2024
Enrollment
815 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, heart failure